Advertisement PFC Pharma Focus, Maccabi To Jointly Provide Clinical Research Optimisation Services - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

PFC Pharma Focus, Maccabi To Jointly Provide Clinical Research Optimisation Services

PFC Pharma Focus (PFC), an internationally recognised clinical research organisation (CRO), has launched a new collaboration with Maccabi HealthCare Services, a not for profit HMO, to provide integrated clinical research optimisation services designed to better meet the needs of the pharmaceutical industry.

PFC said that access to Maccabi’s multidimensional clinical database and patient registries are expected to reduce the risks of clinical research and shorten time to market.

PFC and Maccabi said that the database includes complete anonymised outpatient records from primary care and specialty physicians, laboratory results, comprehensive drug prescription and purchasing information, centralised digitised images and hospitalisation data.

Maccabi’s patient registries include diabetes, cardiovascular, infertility, hypertension, home care, oncology, psychiatry and anticoagulation treatment.

Maccabi claimed that its fully integrated electronic medical record permits customised queries to physicians to obtain additional information not routinely collected, while safeguarding patient confidentiality.

Ran Frenkel, VP of business development at PFC Pharma Focus, said: “With the power of Maccabi’s database resources and database research capabilities, PFC can now offer clients research planning services, including feasibility studies, patient profiling and real time automated patient recruitment tools.

“Maccabi’s database enables drug safety and outcomes studies, epidemiological studies, and pharmaco-economic research.”

Ehud Kokia, CEO of Maccabi HealthCare Services, said: “We are pleased that through this collaboration with Pharma Focus, Maccabi will be able to leverage its data resources and research experience to expedite the development of new drugs.”